Technical Data
K1851-01F
Kip2, p57 (p57Kip2, Cyclin-dependent Kinase Inhibitor 1C, CDKN1C, Cyclin-dependent Kinase Inhibitor p57)
Description:
p57 protein is a cyclin dependent kinase inhibitor similar to p21 and p27 proteins and acts as a tumor suppressor. The gene encoding for p57 is in a chromosome region that is a common site for loss of heterozygosity in certain diseases. This antibody will help detect p57 and may be useful in determining the functional significance of this protein in a variety of tissues.

Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: 1:50-1:100 for 1 hr at RT
Optimal dilutions to be determined by the researcher.

Positive Control:
Placenta (nuclear staining pattern)

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG125B2Supernatant
SizeStorageShippingSourceHost
1ml-20CBlue IceMouse
Concentration:
Not determined
Immunogen:
Recombinant protein representing a 116aa portion of the amino-terminus of the p57 protein.
Purity:
Supernatant
Form
Supplied as a lyophilized powder in 15mM sodium azide. Reconstitute with 1ml dH2O.
Specificity:
Recognizes p57 Protein. Species Crossreactivity: Human.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Bhuiyan Z A, Yatsuki H, Sasaguri T, et al.. 1. Functional analysis of the p57KIP2 gene mutation in Beckwith-Wiedemann syndrome. Hum.Gen.104:205- 210 (1999). 2.Nagata M, Shibata S, Shigeta M, et al.. Cyclin-dependent kinase inhibitors: p27kip1 and p57kip2 expression during human podocyte differentiation. Nephrol Dial Transplant 14(1):48-51 (1999). 3.Nagata M, Nakayama K-i, Terada Y, et al.. Cell cycle regulation and differentiation in the human podocyte lineage. American Journal of Pathology 153(5):1511-1520 (1998). 4.Watanabe H, Pan Z-Q, Schreiber-Agus N, et.al.. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57 KIP2 requires binding to proliferating cell nuclear antigen. Proc. Natl. Acad. Sci. USA 95:1392-1397 (1998). 5.Chung W-Y, Yuan L, Feng L, et al.. Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms tumors. Human Molecular Genetics 5(8):1101-1108 (1996). 6.Tokino T, Urano T, Furuhata T, et al.. Characterization of the human p57 KIP2 gene: alternative splicing, insertion/deletion polymorphisms of VNTR sequences in the coding region, and mutational analysis. Hum. Genet. 97:625-631 (1996). 7.Kondo M, Matsuoka S, Uchida K, et al.. Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5. Oncogene. 12:1365-1368 (1996). 8.Matsuoka S, Edwards M C, Bai C, et al.. p57KIP2 a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor supressor gene. Genes & Development. 9:650-662 (1995).